Introduction
The nuclear factor-kappa B (NF-kB) signal transduction pathway is an intricately regulated cellular pathway that ultimately controls the expression of hundreds of human genes, often as a means to deal with cellular or organismal stress. The effects of the upstream components of the pathway on the activity of NF-kB transcription factors usually determine the output of this pathway: modulation of target gene expression. As such, the net effect of NF-kB signaling can be affected by intervention, either by mutation or pharmacological means, at multiple steps. This review covers situations in which mutations in NF-kB signaling are involved in human diseases. Epigenetic mis-regulation of NF-kB signaling and therapeutic intervention in NF-kB signaling are discussed in other reviews in this edition (see Basse`res and Baldwin, 2006; De Bosscher et al., 2006; Gilmore and Herscovitch, 2006, this issue) .
The vertebrate NF-kB transcription factor family includes five members: p50/p105, p52/p100, c-Rel, RelA (aka p65) and RelB (see Gilmore, 2006, this issue) . These transcription factors are related through an N-terminal domain of approximately 300 amino acids, called the Rel homology domain (RHD), which contains sequences required for DNA binding, dimerization, nuclear localization and inhibitor (IkB) binding. There are two subfamilies to the NF-kB family: the NF-kB and the Rel proteins. The NF-kB p105 and p100 proteins are distinguished by their C-terminal IkB-like inhibitory domains that contains multiple copies of the ankyrin (ANK) repeat. Consequently, the NF-kB subfamily proteins are synthesized as large precursor proteins (p105 and p100) that are processed by proteasome-mediated partial proteolysis to their mature, DNA-binding forms, p50 and p52, respectively. The Rel proteins (c-Rel, RelA and RelB) are not processed and contain C-terminal transactivation domains, which are unrelated to one another and are often quite variable across species, even for a single Rel family member. For most part, all NF-kB and Rel proteins can form homodimers and heterodimers that can bind to DNA target sites called kB sites; however, the affinities of individual subunits for one another and for various kB target sites can vary greatly.
Activation of the NF-kB signaling pathway is regulated at several levels (see Hayden and Ghosh, 2004; Gilmore, 2006, this issue) . Nevertheless, it is still clear that the primary regulation of the NF-kB pathway is through the association of NF-kB complexes with IkB inhibitor proteins. As with NF-kB complexes, there are multiple human IkB proteins including IkBa, IkBb, IkBe, and the lesser-studied IkBz and MAIL proteins. In addition, the full-length NF-kB p105 and p100 proteins function as IkBs owing to their C-terminal ANK domains. The IkBs contain multiple copies of the ANK repeat, which mediate their interaction with the RHD sequences of a given NF-kB dimer. In many cell situations, the principal latent NF-kB complex is a p50-RelA-IkBa trimer, which is primarily located in the cytoplasm and is incapable of binding to DNA. Activation of this canonical NF-kB pathway, in response to various extracellular signals, proceeds via phosphorylation of IkBa at two N-terminal serines by the IkB kinase (IKK). This promotes ubiquitination of IkBa by the SCF-bTrCP complex and its degradation by the proteasome. Thus, forms of IkBa that are mutated or deleted of the two inducible Ser residues act as non-inducible, super-repressors of NF-kB activation. After degradation of IkBa, the liberated NF-kB complex is free to bind to appropriate target genes. However, the activity of NF-kB transcription complexes can also be modulated by a variety of post-translational modifications and interactions with other proteins, such as other transcription factors or coactivators (see Perkins, 2006, this issue) . A second, noncanonical NF-kB signaling pathway involves activation of the p100-RelB complex to p52-RelB in response to specific extracellular ligands (see Scheidereit, 2006, this issue) .
For activation of the canonical NF-kB pathway, IKK is a multimeric complex consisting of two catalytic subunits, IKKa and IKKb, and a regulatory subunit called NF-kB essential modulator (NEMO). Activation of the non-canonical p100-RelB complex generally proceeds through NF-kB inducing kinase, a kinase that acts on an IKKa homodimer complex, lacking NEMO. The regulation of the IKK complex is discussed in detail elsewhere (see Perkins, 2006; Scheidereit, 2006, this issue) ; however, some discussion of NEMO is warranted for discussions herein. NEMO acts as a scaffold and sensing protein for the canonical IKK complex. NEMO is mostly composed of domains with coiled-coil structure, which are amphipatic helices, and contains a zinc finger at the C terminus (Figure 1 ). Precisely how NEMO participates in IKK activation is still unclear, but NEMO can be modified by ubiquitination and phosphorylation, perhaps to control its oligomeric state, during signal processing and NEMO can bind to K63-ubiquinated substrates (see Perkins, 2006; Scheidereit, 2006, this issue) .
The recent identification of human genetic diseases and somatic cell mutations that affect components of the NF-kB signaling pathway has provided a wealth of information regarding how perturbations of this pathway impact normal and disease physiology. This review focuses on mutations in the core signaling components of the NF-kB pathway, but also mentions other diseases that involve mutations that affect NF-kB signaling (see also Orange et al., 2005) .
Inherited human genetic disorders caused by mutations in the NF-jB signaling pathway
NEMO-related diseases
The human gene encoding NEMO is located on the X chromosome (Xq28) and NEMO mutations have been associated with several distinct X-linked genetic diseases (Table 1 and Figure 1 ). The first identified NEMO-defective pathology, incontinentia pigmenti (IP, OMIM#308300), is a complex genodermatosis that is lethal in males and specifically affects females (Berlin et al., 2002) . Although the phenotypes of IP patients are quite variable, a constant feature of the disease is a severe skin inflammation that usually starts within 2 weeks after birth. The inflammatory rash (Vesicular stage) is followed by a hyperproliferation of keratinocytes in the epidermis (Verrucous stage) and an accumulation of melanocytes that produce high amounts of melanin (Pigmented stage). At the final step of the process (Atrophic stage), the cutaneous lesions start to regress, leaving behind hypopigmented areas. The complete IP disease process takes weeks or months and, in rare cases, can restart during the teenage years or adulthood, usually following an infection. Besides this dermatosis, IP patients can also exhibit dental abnormalities (missing and deformed teeth), ocular problems (retinal detachment and strabismus), hair defects or, in the most severe cases, central nervous system dysfunctions (epilepsy and mental retardation).
Seventy to 80% of IP patients carry the same genomic deletion that eliminates exons 4-10 of the NEMO gene (Smahi et al., 2000) (D(IP), Figure 1 ). As a consequence, a short version of NEMO is produced that retains the ability to interact with IKKa and IKKb, but is no longer able to activate the NF-kB pathway in response to stimulation. For example, activation of NF-kB in response to tumor necrosis factor (TNF) is abolished in IP cells, resulting in a high level of apoptotic cell death. This IP-associated defect in NF-kB activation is the likely cause of miscarriage of the male fetus during pregnancy. In contrast, IP females are mosaic given that 
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Figure 1 NEMO mutations in human pathology. Mutations generating IP (red), EDA-ID) (blue) and immunodeficiencies without EDA (green) (Smahi et al., 2000; Zonana et al., 2000; Aradhya et al., 2001a; Aradhya et al., 2001b; Do¨ffinger et al., 2001; Jain et al., 2001; Fusco et al., 2004; Orange et al., 2004; FilipeSantos et al., 2006; Puel et al., 2006) (Zonana et al., 2000; Do¨ffinger et al., 2001; Jain et al., 2001; Aradhya et al., 2001a In contrast, the association of NEMO mutations with the EDA-ID defect in skin adnexes development is more puzzling. Because morphogenesis of all the affected appendages, such as hair, sweat glands and teeth, is dependent upon a specific interaction between the TNF-like ligand ectodysplasin A and its receptor EDAR (Mikkola and Thesleff, 2003) , the analysis of EDA-ID pathology has revealed an unexpected link between ectodysplasin signaling and NF-kB activation, involving NEMO. That is, ectodermal dysplasia (but without the ID pathology) can also be associated with mutations in the genes encoding the ligand ectodysplasin A, its receptor EDAR, or the adaptor protein EDAR-associated death domain, all of which act upstream of NEMO-dependent activation of NF-kB.
Additional physiological dysfunctions have been reported in some EDA-ID patients. In two independent cases, osteopetrosis, which is caused by defective osteoclast function and results in an excess of bone mass, and lymphedema, which is caused by impaired development of lymphatic vessels, were observed (Smahi et al., 2000; Do¨ffinger et al., 2001) . The phenotype of this pathology (EDA-ID with osteopetrosis and lymphedema (OL-EDA-ID)) supports the view that NF-kB plays an important role in skeletal development and has revealed a new role for this transcription factor in lymphatic vessel physiology. The NEMO mutation responsible for OL-EDA-ID is a mutation of the stop codon (X420W) that adds 27 extra amino acids to the NEMO protein and reduces its stability.
More recently, a heterogeneous series of immunodeficient patients that do not exhibit any associated signs of Abbreviations: aa, amino acids; Chr., chromosome; CNS, central nervous system; C-ter, C terminus; EDA-ID, anhidrotic ectodermal dysplasia with immunodeficiency; IKK, IkB kinase; IRAK, interleukin-1R-associated kinase; MFT, multiple familial trichoepithelioma; NEMO, NF-kB essential modulator; NF-kB, nuclear factor-kappa B; N-ter, N terminus; nuc, nucleotides; OL-EDA-ID, EDA-ID with osteopetrosis and lymphedema; ZF, zinc finger.
EDA were also shown to carry NEMO mutations (Tobin et al. 2003; Niehues et al., 2004; Orange et al., 2004; Filipe-Santos et al., 2006; Puel et al., 2006) ( Figure 1 ). All affected patients suffered from recurrent infections, often Mycobacteria-related. Specific impaired cell responses have been assigned to some of these patients. For instance, two recently described patients, who harbor missense mutations in the oligomerization domain of NEMO, present with reduced IL-12 synthesis in response to CD40 (Filipe-Santos et al., 2006) . In summary, NEMO mutations can produce a remarkably large number of defects in humans. At one end of the spectrum, abolished NF-kB activation caused by NEMO rearrangement or severe truncations of NEMO is responsible for IP whereas at the other end, missense mutations or short truncations of NEMO are responsible for EDA-ID or pure immunodeficiency-associated diseases. Nevertheless, it is not always easy to establish such a clear-cut phenotype/ genotype relationship. This is mostly due to the additional layer of complexity provided by the X-linkage of NEMO and by the multi-domain structure of the NEMO protein, which allows connection to various signaling pathways. For example, several missense mutations that have been associated with IP and EDA-ID pathologies occur all along the NEMO protein (Do¨ffinger et al., 2001; Fusco et al., 2004) ( Figure 1 ). Therefore, it remains to be fully understood how these mutations affect, at the molecular level, the function of NEMO and how they impact upon NF-kB activation by specific stimuli.
IkBa-related immune deficiency
Two patients exhibiting a severe immunodeficiency syndrome sharing many similarities with EDA-ID have been reported Janssen et al., 2004) . Strikingly, both individuals showed, in addition to an impaired innate immune response, a T-cell proliferation defect that resulted in a lack of memory T cells. Indeed, both patients were unable to mount an immune response to recall antigens, and their purified T cells were unresponsive to stimulation by mitogens in vitro. Such defects are not usually observed in NEMO-related EDA-ID patients. Despite a defective NF-kB activation process, no NEMO mutations were identified and activation of IKK in cells from these patients was normal. The molecular defect was identified as a specific impairment of IkBa degradation, whereas degradation of IkBb and IkBe was normal. Upon sequencing, a heterozygous mutation affecting the gene encoding IkBa was found, indicating a dominant mode of genetic transmission. Interestingly, in both cases, the mutated residue was Ser-32, which is one of the two phospho-acceptor sites for IKK to trigger IkBa degradation. The existence of multiple forms of EDA-ID (X-linked, due to NEMO mutations, and autosomal dominant, due to IKBA gene mutations) suggests that other components of the NF-kB activation pathway, in addition to NEMO and IkBa, can also be mutated in humans to generate an EDA-ID-related disease.
IRAK-4-related pathology IL-1R-associated kinase (IRAK)-4 is a member of the IRAK family of protein kinases that plays an essential role in IL-1 receptor and Toll-like receptor (TLR) signaling pathways (Suzuki et al., 2002a) . IRAK-4 interacts with both Myd88 and IRAK-1, and its catalytic activity is required for IRAK-1 activation. Once hyperphosphorylated by IRAK-4, IRAK-1 associates with TNF receptor-associated factor (TRAF) 6, triggering activation of both NF-kB and mitogen-activated protein kinase (MAPK) pathways.
Several patients exhibiting recurrent bacterial infections, especially caused by extracellular pyogenic bacteria such as Streptococcus pneumoniae or Staphylococcus aureus, have been identified as carriers of IRAK-4 mutations (Medvedev et al., 2003; Picard et al., 2003) . In all cases, the mutation affects the kinase domain of IRAK-4, either resulting in its truncation or impairing its activity. As a consequence, defective cell responses were observed upon treatment with IL-1, IL-18 and various TLR ligands, such as LPS, peptidoglycan, zymosan or flagelin, whereas the response to TNF was unaffected. Moreover, activation of both NF-kB and p38 signaling pathways are defective in cells from such patients. This suggests that the immodeficiency caused by IRAK-4 mutations is not exclusively linked to defective NF-kB signaling, but also involves perturbed MAPK signaling.
Cylindromatosis Cylindromatosis (OMIM#132700) is a rare, recessive genetic disease characterized by the formation of benign tumors, called cylindromas, in hairy parts of the body, mostly the scalp (Bignell et al., 2000) . Cylindromas are considered as originating from a transformation event specifically affecting the folliculo-sebaceous unit that produces hair and its associated glands. The mutated gene, CYLD, encodes a tumor suppressor protein (Bignell et al., 2000) that can negatively regulate NF-kB activation (Brummelkamp et al., 2003; Kovalenko et al., 2003; Regamey et al., 2003; Trompouki et al., 2003) . CYLD is a member of the deubiquitinase family of enzymes that can specifically hydrolyse poly-ubiquitin chains of the 'K63' type. Poly-ubiquitination is a post-translational modification that is used to influence the fate or function of myriad proteins (Welchman et al., 2005) . Usually, poly-ubiquitin chains are formed through covalent linkages involving Lys-48 of ubiquitin, and the substrate proteins modified in this way are recognized by the proteasome and degraded. More recently, a second type of polyubiquitination, occurring at Lys-63 (K63) of ubiquitin, has been shown to control various cellular functions but not through degradation. One of these K63-ubiquitincontrolled functions appears to be IKK activation (Chen, 2005; Perkins, 2006, this issue) and CYLD may act at this level by interacting directly with NEMO and TRAF2 to control their ubiquitination status. More recently, CYLD has been shown to bind to and deubiquitinate Bcl-3, which prevents nuclear accumulation of Bcl-3 (Massoumi et al., 2006) .
Most CYLD mutations identified in cylindromatosis are frameshift or nonsense mutations that remove all or part of the catalytic domain of CYLD (Bignell et al., 2000; Poblete-Gutie´rrez et al., 2002; Hu et al., 2003; Scheinfeld et al., 2003; Tobin et al., 2003; Bowen et al., 2005; Heinritz et al., 2006) (Figure 2 ). In addition, a few missense mutations have been identified, but how they affect CYLD function is unclear . It has been proposed that CYLD inactivating mutations induce tumorigenesis by causing chronic NF-kB activation, given that NF-kB can regulate numerous genes involved in protection against apoptosis or in control of the cell cycle: more specifically, chronic activation of the TRAF2 to NF-kB pathway may promote survival and inflammation, while enhanced p50 2 -Bcl-3-or p52 2 -Bcl-3-dependent gene expression may increase cell proliferation. Dysregulation of both classes of NF-kB targets would be expected to participate in cylindroma formation. Nevertheless, it cannot be ruled out that effects on other signaling pathways, which are under CYLD control, such as the c-Jun N-terminal kinase pathway (Reiley et al., 2004) , also play a role in cylindromatosis.
Multiple familial trichoepithelioma
Multiple familial trichoepithelioma (MFT, OMIM# 601606) has been considered for years as distinct from cylindromatosis because affected patients exhibit tumors derived from the hair follicle rather than from the associated glands. Nevertheless, some CYLD patients harbor trichoepitheliomas intermingled with cylindromas (Poblete-Gutie´rrez et al., 2002). Thus, whether there was a genetic relationship between the two diseases remained unclear; however, it is now known that some MFT patients also have mutations in CYLD (Salhi et al., 2004; Zhang et al., 2004; Zheng et al., 2004) (Figure 2 ), suggesting that cylindromatosis and MFT are two distinct manifestations of the same genetic defect. This discovery supports the view that precursor cells of the folliculo-sebaceous hair unit are indeed the cell types that become transformed upon CYLD dysfunction.
Somatic cell mutations in genes encoding NF-jB signaling molecules in human cancers are primarily found in lymphomas REL gene alterations in human B-cell malignancies The human REL gene, located at chromosomal position 2p16.1-15, is probably the most common target for somatic cell genetic alteration among the NF-kB signaling components. REL has been affected by gene amplifications, deletions and point mutations, primarily in human B-cell malignancies. In addition, REL is the only NF-kB transcription factor for which there is a retroviral counterpart, that is, the acutely oncogenic v-Rel oncoprotein of the avian Rev-T retrovirus (reviewed by Gilmore, 1999) . Consistent with a role for REL in human B-cell malignancy, v-Rel causes rapidly fatal lymphoid cell (primarily B-cell) lymphomas and leukemias in infected chickens, and likely serves as a model for how REL contributes to human B-cell malignancy. The REL protein is a 587 amino-acid polypeptide with an N-terminal RHD and a C-terminal domain that contains two transactivation subdomains (Gilmore et al., 2004) .
REL gene amplifications have been detected at significant frequency in many types of human B-cell, and to a lesser extent T-cell, lymphoma (Table 2, see also Gilmore et al., 2004) . These diseases include Hodgkin's lymphoma (HL) (B 50% REL amplifications) and non-Hodgkin's B-cell lymphomas (B10-20%). In these cancers, one may find anywhere from 4 to approximately 75 copies of the locally amplified REL locus. Although several other genes lie in the area of the REL amplicons in these tumors, REL is the only gene in the minimal region of overlap in these lymphoma-associated amplifications (Fukuhara et al., 2006; LM Staudt, personal communication) .
The simple model for REL-mediated oncogenesis in these cases of REL amplification is that the increased gene copy number leads to overexpression of REL protein, which overwhelms the IkB inhibitory system to lead to chronic and oncogenic activation of REL target genes. Indeed, overexpression of human REL is sufficient to transform and immortalize primary chicken lymphoid cells in culture (Gilmore et al., 2001; Starczynowski et al., 2003; Fan et al., 2004) . Conversely, the primary defect in c-rel knockout mice is one of B-cell survival and proliferation, in that c-Rel null B cells do not proliferate in response to many mitogens and show increased apoptosis (reviewed by Gerondakis et al., 2006, this issue) . These observations suggest that too much REL-induced gene expression leads to enhanced (Riehermann and Sorg, 1993) , but no evidence for CYLD interacting with the cytoskeleton has yet been provided. Instead, the third CAP-gly domain of CYLD represents the binding site for NEMO (Saito et al., 2004) . A PXQXS/T-like motif that allows interaction with TRAF-2 is indicated. 'C' and 'H' boxes are subdomains of the catalytic domain that contain the active cysteine and histidine residues. (Pham et al., 2005) . Despite the common amplification of the REL locus, there has been limited analysis of REL protein expression in primary human B-cell lymphomas. Namely, it is not clear whether REL gene amplification faithfully translates into increased REL protein expression. Several reports have used immunohistochemistry to analyse REL expression in Hodgkin's and nonHodgkin's B-cell lymphoma samples. In two reports (Donnelly et al., 2001; Barth et al., 2003) , lymphoma samples with REL gene amplification showed increased nuclear REL staining as compared to samples without REL gene amplification. In contrast, Houldsworth et al. (2004) did not find a correlation between nuclear REL expression and REL gene amplification: that is, some DLBCL samples with a high level of REL gene amplification had less nuclear REL staining than DLBCL samples with no REL gene amplification. Xiao et al. (2004) detected nuclear REL staining in a high percentage (B85%) of Reed-Sternberg cells of classic HL. Nuclear REL staining has also been seen in the majority of 9 cases of Hodgkin's-like large cell lymphoma (Garcia et al., 2005) , and in 5 of 6 and 7/7 cases of mediastinal large B-cell lymphoma (Savage et al., 2003; Feuerhake et al., 2005) . Moreover, Rodig et al. (2005) have recently presented data suggesting that nuclear REL staining and high level of expression of adaptor protein TRAF1, a possible REL target gene product, can be used to distinguish classical HL cells from other types of B-cell lymphomas, such as anaplastic large cell lymphoma, lymphocyte predominant HL, and nonmediastinal DLBCL.
These lymphoma-based studies on REL protein expression have made the tacit assumption that only lymphomas with substantial nuclear REL staining can have REL-driven oncogenic activity. However, it is important to note that in in vitro-transformed chicken spleen cells REL (and v-Rel) appear to be primarily cytoplasmic by immunofluorescence (Starczynowski et al., 2003) , and yet the evidence is quite convincing that these oncogenic proteins are continually entering the nucleus to drive the gene transcription that causes transformation and immortalization of these cells (Gilmore, 1999; Gilmore et al., 2004) . Thus, one cannot assume that cytoplasmic REL staining of lymphoma samples dictates the presence of only inactive REL complexes. On the other hand, given that c-Rel complexes are normally in the nucleus of mature B cells, one cannot determine by immunolocalization whether nuclear REL staining in specific human B-cell lymphomas is driving malignancy or is simply a marker for the developmental stage of the given tumor.
One additional confusing aspect of the correlation between REL gene amplification and human B-cell lymphoma is that several Rel/NF-kB target genes, including genes encoding cytokines, chemokines and antiapoptotic factors, have been reported to be overexpressed in only one type of DLBCL, classified as an activated B-cell (ABC)-like DLBCL based on cDNA microarray expression data (Alizadeh et al., 2000; Rosenwald et al., 2002) . However, in those studies REL gene amplifications, and the consequent overexpression of REL mRNA, were confined exclusively to those lymphomas with the germinal center B-cell (GCB) lymphoma mRNA expression pattern Bea et al., 2005) . Moreover, expression of the Houldsworth et al. (1996 Houldsworth et al. ( , 2004 ; Barth et al. (1998 Barth et al. ( , 2001 NF-jB mutations and human disease G Courtois and TD Gilmore super-repressor form of IkBa blocked the growth of DLBCL cell lines with the ABC-like expression pattern, but not DLBCLs with the GCB microarray expression pattern (Davis et al., 2001) . Therefore, as suggested by Shaffer et al. (2002) , increased REL activity provided by REL gene amplification may be important at an early, or perhaps stem-cell, stage of GCB tumor development. Alternatively, REL gene amplification may be important for GCB-like DLBCL cell growth in vivo but not in vitro. Indeed, it is curious that there are no human B-cell lymphoma cell lines with well-characterized REL gene amplification, suggesting that high level REL gene expression may be incompatible with in vitro lymphoma cell growth. However, it should be noted that an independent analysis of a different panel of DLBCLs using the Staudt cDNA expression criteria found REL gene amplifications in about 20% of the samples in both the ABC and GCB molecular subtypes (Houldsworth et al., 2004) .
REL gene rearrangements and point mutations REL gene rearrangements and deletions have been detected only rarely in human lymphomas. In the bestcharacterized case, the RC-K8 DCLBL cell line has undergone (at least) two mutagenic events in the REL pathway: first, owing to a large deletion on chromosome 2, a chimeric REL protein (REL-NRG) is made in which the REL DNA-binding/dimerization domain is fused to sequences of unknown function (Non-RelGene); and second, there are inactivating mutations in the gene encoding IkBa, such that no IkBa protein is produced (Lu et al., 1991; . Nuclear extracts of RC-K8 cells contain high levels of kB site DNAbinding complexes that consist of combinations of p50, wild-type REL and REL-NRG; furthermore, a number of known Rel/NF-kB target genes, including BCL-x, TRAF1, Bfl-1/A1, ICAM-1 and A20, are expressed at high levels in RC-K8 cells . A requirement for REL activity for the growth of RC-K8 cells is suggested by the finding that overexpression of IkBa blocks the proliferation of RC-K8 cells . Thus, one reasonable model for the role of REL signaling in RC-K8 cells is that the effect of constitutive REL nuclear activity, caused by the lack of IkBa protein, is adjusted to an optimal oncogenic level by cooperation with non-activating REL-NRG dimers. REL gene rearrangements have also been detected in two classical HL tumor samples: in one case, the REL gene is translocated to a position near the light chain enhancer and in the second case, there is an alteration near the 3 0 end of REL such that a C terminallytruncated REL protein is synthesized that shows constitutively nuclear staining . In addition, in one HL cell line, an Epstein-Barr virus genome has integrated near to REL, resulting in increased REL mRNA expression (Luo et al., 2004) . Lastly, a Ser-to-Pro point mutation in the transactivation domain of REL (at Ser-525) has recently been detected in two human B-cell lymphomas (Starczynowski et al., 2006) . The REL-S525P protein shows increased transforming ability in chicken spleen cells and altered transactivation properties. Interestingly, in one of the lymphoma patients the S525P mutation is a germline mutation, suggesting that this alteration could be a predisposing mutation for lymphoma. It would not be surprising if other human B-cell lymphomas, with or without REL gene amplification, have activating mutations in REL, especially given that a variety of point mutations and deletions within the REL transactivation domain can enhance the in vitro transforming activity of REL (Starczynowski et al., 2003 (Starczynowski et al., , 2005 .
In contrast to REL, there have been no consistent reports of gene amplification or chromosomal alterations of RELA or RELB in human lymphoid cell malignancies, nor have RELA or RELB been shown to transform lymphoid cells in any cell or animal model system (Fan et al., 2004) . However, in one multiple myeloma patient, a somatic cell mutation in RELA resulted in a C-terminal amino-acid substitution (E494D) that alters the DNA-binding and transactivation properties of RelA (Trecca et al., 1997) .
NFKB2 gene alterations lead to the expression of C terminally-truncated p100 proteins in some B-and T-cell leukemias and lymphomas The human NFKB2 gene locus (chromosome 10q24) has 3 0 structural alterations in about 2% of human B-and T-cell leukemias/lymphomas, including cutaneous B-and T-cell lymphomas, non-HLs, B-cell chronic lymphocytic leukemia (CLL) and multiple myelomas (reviewed by Neri et al., 1996) . These tumor-associated chromosomal changes result in structural alterations in NFKB2 such that sequences encoding all or portions of the ANK repeat domain of p100 are removed, but sequences encoding p52 remain intact. These rearrangements in NFKB2 can be due to chromosomal translocations or chromosomal deletions. In some cases, these changes probably come about as a consequence of aberrant immune cell gene rearrangement; for example, in one B-cell lymphoma, a chromosomal translocation results in exons encoding residues from the constant region of the immunoglobulin heavy chain being placed just 3 0 to exons encoding the RHD of p100, suggesting that incorrect class switching generated the hybrid locus (Neri et al., 1991) . More recently, a point mutation in exon 21 of NFKB2 that creates a stop codon at 775, has been detected in several human B-and T-cell lines, including the well-known Jurkat and Daudi cell lines (Derudder et al., 2003) .
Several lines of evidence suggest that these C terminally-truncated p100 proteins do contribute to human lymphoid cell malignancies. First, the altered NFKB2 genes and their encoded truncated p100 proteins (and sometimes processed p52) are often overexpressed, whereas the normal p100-encoding allele and protein are often deleted or not expressed (Thakur et al., 1994; Derudder et al., 2003) . Second, some of these truncated p100 proteins have been shown to be weakly oncogenic in mouse fibroblasts (Ciana et al., 1997) , even though none has been demonstrated to be oncogenic in any lymphoid cell model in transgenic mice or in tissue culture. Third, mice with a knock out of nfkb2 sequences encoding the C-terminal sequences of p100 have increased numbers of T lymphocytes, enlarged lymph nodes and gastric hyperplasia (Ishikawa et al., 1997) . Fourth, in two large-scale retroviral integration screens for mouse lymphoma genes, retroviral integrations in 3 0 coding regions of nfkb2 (and nfkb1) were detected (Lund et al., 2002; Suzuki et al., 2002b) .
It is likely that these truncated p100 proteins contribute to oncogenesis as constitutive activators of kB site transcription. For example, the C terminally truncated p100 proteins from tumor cells are generally nuclear proteins when overexpressed in tissue culture cells (Migliazza et al., 1994; Zhang et al., 1994) ; homodimers or heterodimers containing the truncated p100 proteins can bind to DNA (Thakur et al., 1994; Zhang et al., 1994; Chang et al., 1995; Derudder et al., 2003) , and the tumor-specific p100 proteins have an increased ability to activate transcription in kB-site reporter gene assays (Chang et al., 1995; Epinat et al., 2000; Kim et al., 2000) . Because the deletions in NFKB2 invariably result in the removal of residues important for the regulated processing of p100 to p52 (Xiao et al., 2001) , the C-terminal truncations sometimes result in increased production of p52-containing dimers (Thakur et al., 1994; Derudder et al., 2003) . Consistent with the increased processing model, p52 is overexpressed in several human, albeit non-lymphoid, cancers (Bours et al., 1994; Dejardin et al., 1995; Cogswell et al., 2000) . In short, these p100 truncations may promote the activity of the non-canonical p52-RELB NF-kB pathway. However, the C-terminal truncations in p100 also remove a caspase-8 recruitment 'death domain' (Wang et al., 2002) , suggesting that these p100 truncations could also contribute to oncogeneis by rendering cells more resistant to apoptotic stimuli.
Inactivating mutations in genes encoding IkB proteins in HL lead to constitutive NF-kB activity HL is a common B-cell lymphoma that is thought to arise from the malignant conversion of a GCB. The malignant cell in HL is the Hodgkin and ReedSternberg (HRS) cell that is found at a low frequency in diseased lymph nodes, where it is surrounded by reactive immune cells. Both HL primary tumor samples and HL cell lines have constitutively active p50-RELA and p50-REL complexes, and generally little or no stable IkBa protein can be detected in these cells (Bargou et al., 1996 (Bargou et al., , 1997 Cabannes et al., 1999) .
In several of these HL cells and perhaps as many as 10% of HL HRS cell biopsy samples, the lack of IkBa is due to loss-of-function mutations (e.g., small insertions, deletions or nonsense) in one allele of the IKBA gene couples with the deletion or inactivation of the second IKBA allele (Wood et al., 1998; Cabannes et al., 1999; Jungnickel et al., 2000; Emmerich et al., , 2003 . As a consequence of the constitutive NF-kB signaling, several NF-kB target genes are overexpressed in HL cells, including ones encoding antiapoptotic proteins (such as A1, c-IAP2, TRAF1 and Bcl-X L ) and growth-promoting proteins (including cyclin D2, CD86 and CD40) (Hinz et al., 2001) . Importantly, re-expression of IkBa can lead to apoptosis in these cells (Bargou et al., 1997; Hinz et al., 2001) , indicating that the loss of IkBa is important for the pathology.
Inactivating mutations in IkBe have also been detected in some HRS cells (Emmerich et al., 2003) . Interestingly, an extensive screen of mouse lymphomas has identified retroviral insertions near the genes encoding IkBa and IkBe (Suzuki et al., 2002b) . In HL cells without IkB mutations, the constitutive NF-kB activity and high turnover of IkBa may be the result of epigenetic alterations, such as the secretion of an autocrine NF-kB-inducing factor by these cells Krappmann et al., 1999) ; however, it cannot be ruled out that these HL cells do not have other mutations in the NF-kB signaling pathway. Moreover, REL gene amplifications are often found in HL samples ( Table 2 ). As discussed above, inactivating mutations in IkBa are also present in the RC-K8 DLBCL cell line ; however, inactivating IkBa mutations have not yet been detected in primary tumor samples from DLBCLs or mediastinal large B-cell lymphomas (Thomas et al., 2004; Takahashi et al., 2006) .
Gene rearrangements lead to increase expression of the NF-kB co-activator BCL-3 The BCL-3 locus is located at chromosome position 19q13 and encodes an IkB-like protein that, unlike most other IkBs, serves as a co-activator for p50 and p52 homodimers. Some patients with B-cell CLL have a characteristic t(14:19) chromosomal translocation in which the BCL-3 gene becomes positioned 3 0 to the switch region of the immunoglobulin heavy chain gene (from chromosome 14) (Ohno et al., 1990; McKeithan et al., 1997) . The 5 0 end of the BCL-3 gene can be located quite near to the breakpoint or up to 16 kbp away; however, inevitably the translocation results in increased expression of BCL-3 mRNA and protein (McKeithan et al., 1997) . In addition, t(14;19) translocations involving BCL-3 have been identified in some lymphomas (Nakagawa et al., 1995; Yano et al., 1995; McKeithan et al., 1997; Au et al., 2002; Soma et al., 2006) and occasionally in lymphoproliferative disorders (Michaux et al., 1996) ; furthermore, other genetic alterations on chromosome 19 may also lead to increased BCL-3 expression (Schlette et al., 2005) . The hypothesis that increased expression of BCL-3 contributes to human B-cell malignancies is supported by several findings: (1) transgenic mice in which BCL-3 is under the control of the m heavy chain enhancer develop splenomegaly and have excess mature B cells in their bone marrow and lymph nodes (Ong et al., 1998) ; (2) overexpression of BCL-3 can transform mouse 3T3 cells in culture (Viatour et al., 2004) ; (3) overexpression of BCL-3 can enhance the survival of activated T cells (Mitchell et al., 2001 ) and (4) elevated levels of BCL-3 are seen in many lymphoid and non-lymphoid human tumor samples (Cogswell et al., 2000; Rassidakis et al., 2003; Canoz et al., 2004; Pallares et al., 2004; Ohno et al., 2005; Schlette et al., 2005) . Oncogenically activating mutations within the coding region of BCL-3 have not been identified; however, such mutations may exist in that certain point mutations can enhance the transforming activity of BCL-3 in vitro (Viatour et al., 2004) .
Bcl-3 is a constitutively nuclear protein, has transcriptional activation domains and can associate with p50 and p52 homodimers to act as a transcriptional coactivator (Bours et al., 1993; Fujita et al., 1993; Dechend et al., 1999) . As such, overexpression of BCL-3 is expected to result in increased transcription of genes normally regulated by p52 or p50 homodimers. The genes responsible for BCL-3-induced oncogenesis have not been extensively identified, but may include CY-CLIN D1 (Westerheide et al., 2001) and SLP1 (Viatour et al., 2004) . However, BCL-3 may have cancer-related activities other than facilitating p50/p52 transcription. For example, Caenorhabditis elegans, which has no Rel/ NF-kB protein, nevertheless has a BCL-3 homolog that is induced by DNA damage (Boulton et al., 2002) , and Bcl-3 can also associate with Jun and Fos proteins to induce DNA synthesis in rat fibroblasts (Na et al., 1999) .
Other human disease mutations associated with NF-jB signaling
There are a variety of other human pathologies in which mutations in NF-kB signaling have been associated with human disease. These can be placed into three broad categories: mutations in genes/proteins that modulate NF-kB signaling, but may not be direct components of the pathway; polymorphisms in genes encoding NF-kB signaling proteins and promoter/enhancer mutations in kB sites in NF-kB target genes (Table 3) .
Perhaps not surprisingly, some inherited persistent autoinflammatory and fever diseases are likely to be 'NF-kB diseases'. These include familial Mediterranean fever, cold-induced autoinflammatory syndrome, Crohn's disease, Blau syndrome and inflammatory Cereb and Yang (1994) Abbreviations: CIAS, cold-induced autoinflammatory syndrome; EDA, ectodermal dysplasia; FMF, familial mediterranean fever; IBD, inflammatory bowel disease; IDs, imunodeficiencies; MWS, Muckle-Wells syndrome; NF-kB, nuclear factor-kappa B; NSCL, nonsyndromic cleft lip; PDB, Paget's disease of bone; PL, primary lymphedema; SLE, systemic lupus erythematosus; TRAPS, TNF receptor-associated periodic syndrome; XLP, X-linked lymphoproliferative syndrome.
NF-jB mutations and human disease G Courtois and TD Gilmore bowel disease, all of which appear to be owing to mutations in genes that can act as negative regulators of NF-kB activation (Strober et al., 2006; Ting et al., 2006) . Similarly, mutations in some TLRs appear to change the NF-kB response of individuals to certain pathogens (Orange et al., 2005) or be associated with an increased risk of certain cancers (Chen et al., 2005b) . Much less studied are the roles of mutations either in NF-kB gene promoters (e.g., NFKB1) or in kB sites in NF-kB target gene promoters in human disease susceptibility, although such correlations have been noted (see Table 3 ).
Conclusions and perspectives
Given that transcription factor NF-kB controls hundreds of genes involved in diverse cellular processes (see www.nf-kb.org), it is not surprising that mis-regulation of the pathway by mutation can be involved in diverse pathologies, as described in this review. The primary NF-kB-regulated processes that have been identified as altered by mutation in human disease are inflammation (as in chronic and autoimmune disorders), immunity (e.g., immunodeficiencies) and cell proliferation and survival (e.g., cancer). Generally, it is not clear why specific mis-regulations of the NF-kB pathway result in unique pathologies (e.g., why CYLD defects result in a hair follicle disease). Most of the mutations in NF-kB that have been documented to date result in gross effects on protein function or expression (such as with gene amplification, chromosomal translocation and inactivating mutations). As our ability to detect inherited disease mutations increases, it is likely that we will identify mutations that affect NF-kB signaling, either in core or modifying components, in other types of human disorders, such as developmental, metabolic and neural diseases. In addition, we will no doubt find that more subtle mutation-based alterations in NF-kB signaling are responsible for normal variation between individuals in immunity, disease susceptibility and therapeutic response. The broad role of NF-kB signaling in normal and disease physiology is both its lure and its flaw as a therapeutic target.
